BioRestorative Therapies, Inc. ("BRT" or the "Company")
(OTCBB: BRTX), a life sciences company focused on adult stem
cell-based therapies for various personal medical applications, today
announced the engagement of Tokyo-based Solution Partners Ltd. to
develop strategic alliances in Japan and China for the Company’s
technologies. The agreement includes introductions to potential
strategic partners and other alliance candidates, with the goal of
expansion and development of the Company’s ThermoStem®
program, the Company’s stem cell delivery device used in connection with
the Company’s brtx-DISCTM program and the Company’s brtx-C
Cosmetic program.
Solution Partners, founded by Masami Ishigaki in 2000, is an official
supporting member of Tokyo Metropolitan Hospital Association. Mr.
Ishigaki has served in various financial positions at, among others,
Suntory, Novartis Pharma (Japan), and LVMH Group (Guerlain Japan and
Celine Japan).
“Solution Partners has a strong track record of success in identifying
and negotiating strategic alliances in Japan and China, and we are very
excited to engage Mr. Ishigaki and his firm to identify business
possibilities for us,” said Mark Weinreb, BioRestorative Therapies’
Chief Executive Officer. “These Asian markets are very large, and
represent significant potential opportunities for our proprietary stem
cell programs. We look forward to continuing our work on ThermoStem® and
brtxDISC™ in the U.S. while expanding the worldwide market for our
therapies. In addition, Mr. Ishigaki’s experience in the cosmetics field
is expected to support our goal of licensing brtx-C Cosmetic
technologies to skincare companies.”
About Solution Partners Ltd.
Solution Partners has provided quality improvement programs for medical
care and nursing systems, hospital infection control, hospital
information systems and recruitment services for professional medical
staff. It is also engaged in marketing and sales support for genetic
testing for cancer, developed by Japanese company Genescience Ltd. in
Japan and in China.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com)
develops products and medical procedures using cell and tissue
protocols, primarily involving adult stem cells, including:
-
brtxDISC™ (Disc Implanted Stem Cells)
is an investigational non-surgical treatment for bulging and herniated
lumbar discs that is intended for patients who have failed
non-invasive procedures and face the prospect of surgery. The
treatment involves culturing a patient’s own stem cells and then
delivering them via a proprietary medical device to the damaged region
of the disc in an outpatient procedure.
-
ThermoStem® is a treatment using brown fat stem cells that is
under development for metabolic disorders including diabetes and
obesity. Initial preclinical research indicates that increased amounts
of brown fat in the body may be responsible for additional caloric
burning as well as reduced glucose and lipid levels.
-
brtx-C Cosmetic is based on the development of a human cellular
extract that has been demonstrated in in vitro skin studies to
increase the production of collagen and fibronectin, which are
proteins that are essential to combating the aging of skin. Potential
cosmetic uses are being explored with third parties.
The Company also offers plant stem cell-based facial creams and beauty
products under the Stem Pearls® brand at www.stempearls.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, and such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. You
are cautioned that such statements are subject to a multitude of risks
and uncertainties that could cause future circumstances, events or
results to differ materially from those projected in the forward-looking
statements as a result of various factors and other risks, including
those set forth in the Company's Form 10-K filed with the Securities and
Exchange Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance
on such statements. The forward-looking statements in this release are
made as of the date hereof and the Company undertakes no obligation to
update such statements.
Copyright Business Wire 2014